These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 35008821)

  • 21. Tepotinib Inhibits the Epithelial-Mesenchymal Transition and Tumor Growth of Gastric Cancers by Increasing GSK3β, E-Cadherin, and Mucin 5AC and 6 Levels.
    Sohn SH; Sul HJ; Kim B; Kim BJ; Kim HS; Zang DY
    Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32825724
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Design, synthesis, and Structure-Activity Relationships (SAR) of 3-vinylindazole derivatives as new selective tropomyosin receptor kinases (Trk) inhibitors.
    Duan Y; Wang J; Zhu S; Tu ZC; Zhang Z; Chan S; Ding K
    Eur J Med Chem; 2020 Oct; 203():112552. PubMed ID: 32702585
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Entrectinib: First Global Approval.
    Al-Salama ZT; Keam SJ
    Drugs; 2019 Sep; 79(13):1477-1483. PubMed ID: 31372957
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Activity of Entrectinib in a Patient With the First Reported
    Sigal D; Tartar M; Xavier M; Bao F; Foley P; Luo D; Christiansen J; Hornby Z; Maneval EC; Multani P
    J Natl Compr Canc Netw; 2017 Nov; 15(11):1317-1322. PubMed ID: 29118225
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).
    Drilon A; Siena S; Ou SI; Patel M; Ahn MJ; Lee J; Bauer TM; Farago AF; Wheler JJ; Liu SV; Doebele R; Giannetta L; Cerea G; Marrapese G; Schirru M; Amatu A; Bencardino K; Palmeri L; Sartore-Bianchi A; Vanzulli A; Cresta S; Damian S; Duca M; Ardini E; Li G; Christiansen J; Kowalski K; Johnson AD; Patel R; Luo D; Chow-Maneval E; Hornby Z; Multani PS; Shaw AT; De Braud FG
    Cancer Discov; 2017 Apr; 7(4):400-409. PubMed ID: 28183697
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Entrectinib resistance mechanisms in ROS1-rearranged non-small cell lung cancer.
    Ku BM; Bae YH; Lee KY; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
    Invest New Drugs; 2020 Apr; 38(2):360-368. PubMed ID: 31124056
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mechanisms of Entrectinib Resistance in a Neuroblastoma Xenograft Model.
    MacFarland SP; Naraparaju K; Iyer R; Guan P; Kolla V; Hu Y; Tan K; Brodeur GM
    Mol Cancer Ther; 2020 Mar; 19(3):920-926. PubMed ID: 31871269
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antitumor Activity of Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor, in
    Smith KM; Fagan PC; Pomari E; Germano G; Frasson C; Walsh C; Silverman I; Bonvini P; Li G
    Mol Cancer Ther; 2018 Feb; 17(2):455-463. PubMed ID: 29237803
    [TBL] [Abstract][Full Text] [Related]  

  • 29. NTRK oncogenic fusions are exclusively associated with the serrated neoplasia pathway in the colorectum and begin to occur in sessile serrated lesions.
    Kim JH; Hong JH; Choi YL; Lee JA; Seo MK; Lee MS; An SB; Sung MJ; Cho NY; Kim SS; Shin YK; Kim S; Kang GH
    J Pathol; 2021 Dec; 255(4):399-411. PubMed ID: 34402529
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Entrectinib for the treatment of metastatic NSCLC: safety and efficacy.
    Sartore-Bianchi A; Pizzutilo EG; Marrapese G; Tosi F; Cerea G; Siena S
    Expert Rev Anticancer Ther; 2020 May; 20(5):333-341. PubMed ID: 32223357
    [No Abstract]   [Full Text] [Related]  

  • 31. Overexpression of NCAPG inhibits cardia adenocarcinoma apoptosis and promotes epithelial-mesenchymal transition through the Wnt/β-catenin signaling pathway.
    Zhang X; Zhu M; Wang H; Song Z; Zhan D; Cao W; Han Y; Jia J
    Gene; 2021 Jan; 766():145163. PubMed ID: 32980450
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Frequent amplification of PTP1B is associated with poor survival of gastric cancer patients.
    Wang N; She J; Liu W; Shi J; Yang Q; Shi B; Hou P
    Cell Cycle; 2015; 14(5):732-43. PubMed ID: 25590580
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combating autophagy is a strategy to increase cytotoxic effects of novel ALK inhibitor entrectinib in neuroblastoma cells.
    Aveic S; Pantile M; Seydel A; Esposito MR; Zanon C; Li G; Tonini GP
    Oncotarget; 2016 Feb; 7(5):5646-63. PubMed ID: 26735175
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HER3 PET Imaging Predicts Response to Pan Receptor Tyrosine Kinase Inhibition Therapy in Gastric Cancer.
    Esfahani SA; de Aguiar Ferreira C; Rotile NJ; Ataeinia B; Krishna S; Catalano OA; Caravan P; Yen YF; Heidari P; Mahmood U
    Mol Imaging Biol; 2023 Apr; 25(2):353-362. PubMed ID: 35962301
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting of SPP1 by microRNA-340 inhibits gastric cancer cell epithelial-mesenchymal transition through inhibition of the PI3K/AKT signaling pathway.
    Song SZ; Lin S; Liu JN; Zhang MB; Du YT; Zhang DD; Xu WH; Wang HB
    J Cell Physiol; 2019 Aug; 234(10):18587-18601. PubMed ID: 30953349
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tropomyosin receptor kinase inhibitors: an updated patent review for 2016-2019.
    Bailey JJ; Jaworski C; Tung D; Wängler C; Wängler B; Schirrmacher R
    Expert Opin Ther Pat; 2020 May; 30(5):325-339. PubMed ID: 32129124
    [No Abstract]   [Full Text] [Related]  

  • 37. Entrectinib and other ALK/TRK inhibitors for the treatment of neuroblastoma.
    Pacenta HL; Macy ME
    Drug Des Devel Ther; 2018; 12():3549-3561. PubMed ID: 30425456
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adenovirus-mediated TIPE2 overexpression inhibits gastric cancer metastasis via reversal of epithelial-mesenchymal transition.
    Yin H; Huang X; Tao M; Hu Q; Qiu J; Chen W; Wu J; Xie Y
    Cancer Gene Ther; 2017 Apr; 24(4):180-188. PubMed ID: 28186089
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Suppression of BMX-ARHGAP fusion gene inhibits epithelial-mesenchymal transition in gastric cancer cells via RhoA-mediated blockade of JAK/STAT axis.
    Xu XF; Wang JJ; Ding L; Ye JS; Huang LJ; Tao L; Gao F; Ji Y
    J Cell Biochem; 2019 Jan; 120(1):439-451. PubMed ID: 30216523
    [TBL] [Abstract][Full Text] [Related]  

  • 40. INC280 inhibits Wnt/β-catenin and EMT signaling pathways and its induce apoptosis in diffuse gastric cancer positive for c-MET amplification.
    Sohn SH; Kim B; Sul HJ; Kim YJ; Kim HS; Kim H; Seo JB; Koh Y; Zang DY
    BMC Res Notes; 2019 Mar; 12(1):125. PubMed ID: 30871613
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.